Answers are grounded in this paper and cite their sources.
This review summarizes the current landscape of transcatheter interventions for severe tricuspid regurgitation, highlighting key trials like TRILUMINATE and TRISCEND.
Therapeutic options for patients with severe tricuspid regurgitation range from medical therapy (principally diuretics to manage volume overload), to surgery (most commonly performed concomitantly with other cardiac surgeries, rarely isolated), to investigational transcatheter interventions. The most widely used percutaneous approaches are tricuspid transcatheter edge-to-edge repair (T-TEER) as evaluated in the TriValve registry and TRILUMINATE randomized trial, and transcatheter tricuspid vale replacement (TTVR) as evaluated in the TRISCEND study and ongoing TRISCEND II randomized trial.
No takes yet. Share an insight, caveat, or question.
Bienstock et al. (2023) conducted a review in severe tricuspid regurgitation. Transcatheter interventions (T-TEER and TTVR) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: